Narrative Update • Jun 26
Have your own idea? Try our Stock Screener
U.K. (FTSE) Clinical Research and Equipment Industry Analysis
UpdatedJul 03, 2026
DataAggregated Company Financials
Companies7
- 7D1.4%
- 3M2.2%
- 1Y-14.5%
- YTDn/a
Over the last 7 days, the Clinical Research and Equipment industry has risen 10%, driven by gains from Oxford Nanopore Technologies of 2.0%. During this same period, the Oxford BioDynamics underperformed, falling 48%. However, the industry is down 7.0% over the past year. Looking forward, earnings are forecast to grow by 57% annually.
Industry Valuation and Performance
Has the U.K. Clinical Research and Equipment Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Fri, 03 Jul 2026 | UK£1.4b | UK£323.1m | -UK£164,731,254.00 | 1274.4x | -8.6x | 4.4x |
| Sun, 31 May 2026 | UK£1.6b | UK£323.0m | -UK£166,018,254.00 | 1248.1x | -9.7x | 5x |
| Tue, 28 Apr 2026 | UK£1.4b | UK£318.2m | -UK£167,469,254.00 | n/a | -8.1x | 4.3x |
| Thu, 26 Mar 2026 | UK£1.4b | UK£324.0m | -UK£161,423,254.00 | 8.6x | -8.6x | 4.3x |
| Sat, 21 Feb 2026 | UK£1.6b | UK£304.7m | -UK£159,511,254.00 | 12.1x | -9.8x | 5.1x |
| Mon, 19 Jan 2026 | UK£1.7b | UK£304.6m | -UK£159,441,254.00 | 7.5x | -10.7x | 5.6x |
| Wed, 17 Dec 2025 | UK£1.4b | UK£304.4m | -UK£160,881,254.00 | 8.4x | -8.9x | 4.7x |
| Fri, 14 Nov 2025 | UK£1.5b | UK£304.3m | -UK£163,156,254.00 | 8.2x | -9.3x | 5x |
| Sun, 12 Oct 2025 | UK£1.6b | UK£304.3m | -UK£163,156,254.00 | 8.9x | -10x | 5.4x |
| Tue, 09 Sep 2025 | UK£1.9b | UK£313.5m | -UK£158,190,352.00 | 6.4x | -11.9x | 6x |
| Thu, 07 Aug 2025 | UK£2.3b | UK£291.9m | -UK£160,968,352.00 | 6.4x | -14.2x | 7.8x |
| Sat, 05 Jul 2025 | UK£1.6b | UK£291.9m | -UK£160,968,352.00 | 6.9x | -10.1x | 5.6x |
| Mon, 02 Jun 2025 | UK£1.6b | UK£319.6m | -UK£190,958,890.00 | 5.6x | -8.2x | 4.9x |
| Wed, 30 Apr 2025 | UK£1.6b | UK£313.7m | -UK£192,169,666.40 | 11.5x | -8.4x | 5.2x |
| Fri, 28 Mar 2025 | UK£1.5b | UK£315.6m | -UK£186,160,254.65 | 5.8x | -7.9x | 4.7x |
| Sun, 23 Feb 2025 | UK£1.7b | UK£306.4m | -UK£195,137,615.28 | 6.9x | -8.9x | 5.7x |
| Tue, 21 Jan 2025 | UK£2.1b | UK£307.4m | -UK£195,909,512.88 | 7x | -10.8x | 6.9x |
| Thu, 19 Dec 2024 | UK£2.0b | UK£306.2m | -UK£194,997,887.52 | 7.8x | -10.3x | 6.5x |
| Sat, 16 Nov 2024 | UK£1.8b | UK£305.8m | -UK£193,578,219.28 | 10.2x | -9.5x | 6x |
| Mon, 14 Oct 2024 | UK£2.0b | UK£304.4m | -UK£192,350,536.90 | 10.6x | -10.4x | 6.6x |
| Wed, 11 Sep 2024 | UK£2.0b | UK£293.5m | -UK£192,415,863.00 | 12.5x | -10.3x | 6.7x |
| Fri, 09 Aug 2024 | UK£1.8b | UK£296.8m | -UK£189,197,854.83 | 12.3x | -9.7x | 6.2x |
| Sun, 07 Jul 2024 | UK£1.6b | UK£295.5m | -UK£189,930,390.09 | 11.7x | -8.2x | 5.3x |
| Tue, 04 Jun 2024 | UK£1.6b | UK£295.5m | -UK£189,682,763.07 | 11.4x | -8.6x | 5.5x |
| Thu, 02 May 2024 | UK£1.5b | UK£292.9m | -UK£189,030,205.43 | 7008.3x | -7.9x | 5.1x |
| Sat, 30 Mar 2024 | UK£1.7b | UK£319.1m | -UK£191,411,060.64 | 69.8x | -9.1x | 5.5x |
| Mon, 26 Feb 2024 | UK£1.9b | UK£285.8m | -UK£189,209,049.14 | 6964.3x | -10.3x | 6.8x |
| Wed, 24 Jan 2024 | UK£2.8b | UK£450.3m | -UK£176,628,344.00 | 60.9x | -15.7x | 6.2x |
| Fri, 22 Dec 2023 | UK£3.2b | UK£450.1m | -UK£174,108,918.00 | 53x | -18.4x | 7.1x |
| Sun, 19 Nov 2023 | UK£3.1b | UK£455.8m | -UK£168,862,697.00 | 50.3x | -18.1x | 6.7x |
| Tue, 17 Oct 2023 | UK£2.9b | UK£458.6m | -UK£165,563,414.00 | 50x | -17.3x | 6.2x |
| Thu, 14 Sep 2023 | UK£3.1b | UK£440.4m | -UK£166,916,302.00 | 67.5x | -18.5x | 7x |
| Sat, 12 Aug 2023 | UK£3.3b | UK£476.2m | -UK£126,569,657.00 | 70.6x | -25.9x | 6.9x |
| Mon, 10 Jul 2023 | UK£2.9b | UK£476.3m | -UK£124,539,981.00 | 66.1x | -23.4x | 6.1x |
Price to Earnings Ratio
-23.4x
Current Industry PE
- Investors are pessimistic on the British Life Sciences Tools and Services industry, indicating that they anticipate long term growth rates will be lower than they have historically.
- The 3-year average PS ratio of 5.8x is higher than the industry's current PS ratio of 4.6x.
Past Earnings Growth
- The earnings for companies in the Life Sciences Tools and Services industry have deteriorated over the last three years.
- Revenues have also declined 12% per year.
- This means overall sales from these companies are declining and losses are subsequently expanding as well.
Industry Comparison
How does U.K. Clinical Research and Equipment compare with similar industries?
| GB Market | 1.16% | |
| Healthcare | 2.70% | |
| Life Sciences | 1.42% | |
| Clinical Research and Equipment | 1.42% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| ONT Oxford Nanopore Technologies | UK£1.24 | 2.0% +UK£23.3m | -16.2% | PS5.4x | |
| DXRX Diaceutics | UK£1.46 | 0.7% +UK£846.7k | 25.3% | PE1274.4x | |
| FAB Fusion Antibodies | UK£0.12 | 4.3% +UK£625.1k | 86.0% | PS9.4x |